Resumen
INTRODUCCIÓN:La neurofibromatosis (enfermedad de von Recklinghausen) es una enfermedad autosómica dominante que presenta principalmente manifestaciones cutáneas y neurológicas. El objetivo es describir actualmente si existe o no relación entre las mutaciones encontradas en los pacientes con neurofibromatosis tipo 1 y las características clínicas que presentan.
MÉTODOS:Se realizó un artículo de revisión narrativa para evaluar la relación con el genotipo y fenotipo de los pacientes con neurofibromatosis tipo 1. Se revisaron las bases de datos PubMed, Embase y Lilacs. Se utilizaron los siguientes términos Mesh: Neurofibromatosis, neurofibromatosis tipo 1, genes, genotipo, fenotipo, mutaciones, secuenciación de exoma. Los estudios identificados fueron revisados y analizados. Se presentan los datos de manera cualitativa.
RESULTADOS:De 425 artículos, 62 contenían la información necesaria para hacer el análisis. A pesar de que algunos estudios han presentado evidencia de asociación en relación a las mutaciones encontradas y la clínica, realmente no existe una correlación genotipo-fenotipo comprobada en neurofibromatosis tipo 1. Esto sugiere que para los fenotipos discordantes con genotipo similar existen otros factores que deben considerarse tales como la epigenética, alteraciones genéticas o incluso factores ambientales.
CONCLUSIONES:Es necesario realizar estudios con cohortes más grande de pacientes para seguir estudiando si existe una relación directa o no.
Citas
Kresak JL, Walsh M. Neurofibromatosis: A Review of NF1, NF2, and Schwannomatosis. J Pediatr Genet. 2016;5(2):98-104. DOI: 10.1055/s-0036-1579766.
Ehara Y, Yamamoto O, Kosaki K, Yoshida Y. Clinical severity in Japanese patients with neurofibromatosis 1 based on DNB classification. J Dermatol. 2017;44(11):1262-1267. DOI: 10.1111/1346-8138.13902.
Blakeley JO, Plotkin SR. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro Oncol. 2016 18(5):624-38. DOI: 10.1093/neuonc/nov200.
Anderson JL, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol. 2015;132:75-86. DOI: 10.1016/B978-0-444-62702-5.00004-4.
Tadini G, Milani D, Menni F, Pezzani L, Sabatini C, Esposito S. Is it time to change the neurofibromatosis 1 diagnostic criteria? Eur J Intern Med. 2014;25(6):506-10. DOI: 10.1016/j.ejim.2014.04.004.
Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13(8):834-43. DOI: 10.1016/S1474-4422(14)70063-8.
Zhu L, Zhang Y, Tong H, Shao M, Gu Y, Du X, et al. Clinical and molecular characterization of NF1 patients: Single-center experience of 32 patients from China. Medicine (Baltimore). 2016;95(10):e3043. DOI: 10.1097/MD.0000000000003043.
Anastasaki C, Woo AS, Messiaen LM, Gutmann DH. Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning. Hum Mol Genet. 2015;15;24(12):3518-28. DOI: 10.1093/hmg/ddv103.
Kehrer-Sawatzki H, Mautner VF, Cooper DN. Emerging genotype-phenotype relationships in patients with large NF1 deletions. Hum Genet. 2017;136(4):349-376. DOI: 10.1007/s00439-017-1766-y.
Kehrer-Sawatzki H, Vogt J, Mußotter T, Kluwe L, Cooper DN, Mautner VF. Dissecting the clinical phenotype associated with mosaic type-2 NF1 microdeletions. Neurogenetics. 2012;13(3):229-36. DOI: 10.1007/s10048-012-0332-y.
Kehrer-Sawatzki H, Mautner VF, Cooper DN. Emerging genotype-phenotype relationships in patients with large NF1 deletions. Hum Genet. 2017;136(4):349-376. DOI: 10.1007/s00439-017-1766-y.
Van Minkelen R, van Bever Y, Kromosoeto JN, Withagen- Hermans CJ, Nieuwlaat A, Halley DJ, van den Ouweland AM. A clinical and genetic overview of 18 years’ neurofibromatosis type 1 molecular diagnostics in the Netherlands. Clin Genet. 2014;85(4):318-27. DOI: 10.1111/cge.12187.
Trovó AB, Goloni-Bertollo EM, Mancini UM, Rahal P, de Azevedo WF, Tajara EH. Mutational analysis of the GAP-related domain of the neurofibromatosis type 1 gene in Brazilian NF1 patients. Genet. Mol. Biol. 2004;27(3):326-30. DOI: 10.1590/S1415-47572004000300003.
Zhang J, Tong H, Fu X, Zhang Y, Liu J, Cheng R, et al. Molecular characterization of NF1 and neurofibromatosis type 1 genotype-phenotype correlations in a Chinese population. Sci Rep. 2015;9;5:11291. DOI: 10.1038/srep11291.
Koczkowska M, Chen Y, Callens T, Gomes A, Sharp A, Johnson S, et al Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848. Am J Hum Genet. 2018;102(1):69-87. DOI: 10.1016/j.ajhg.2017.12.001.
Ko JM, Sohn YB, Jeong SY, Kim HJ, Messiaen LM. Mutation spectrum of NF1 and clinical characteristics in 78 Korean patients with neurofibromatosis type 1. Pediatr Neurol. 2013;48(6):447-53. DOI: 10.1016/j.pediatrneurol.2013.02.004
Monroe CL, Dahiya S, Gutmann DH. Dissecting Clinical Heterogeneity in Neurofibromatosis Type 1. Annu Rev Pathol. 2017 24;12:53-74. DOI: 10.1146/annurev-pathol-052016-100228.
Upadhyaya M, Huson SM, Davies M, Thomas N, Chuzhanova N, Giovannini S, et al. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet. 2007 80(1):140-51
Pinna V, Lanari V, Daniele P, Consoli F, Agolini E, Margiotti K, et al. p.Arg1809Cys substitution in neurofibromin is associated with a distinctive NF1 phenotype without neurofibromas. Eur J Hum Genet. 2015 23(8):1068-71. DOI: 10.1038/ejhg.2014.243.
Sabbagh A, Pasmant E, Imbard A, Luscan A, Soares M, Blanché H, et al. NF1 molecular characterization and neurofibromatosis type I genotype-phenotype correlation: The French experience. Hum Mutat. 2013;34(11):1510-8. DOI: 10.1002/humu.22392.
Terzi YK, Sirin B, Hosgor G, Serdaroglu E, Anlar B, Aysun S, et al. Two pathogenic NF1 gene mutations identified in DNA from a child with mild phenotype. Childs Nerv Syst. 2012;28(6):943-6. DOI: 10.1007/s00381-011-1648-x.
Bonatti F, Adorni A, Matichecchia A, Mozzoni P, Uliana V, Pisani F, et al. Patterns of novel alleles and genotype/phenotype correlations resulting from the analysis of 108 previously undetected mutations in patients affected by neurofibromatosis type I. Int J Mol Sci. 2017;18(10). DOI: 10.3390/ijms18102071
Marchand A, Rousseau P, Croue A, Vidaud D, Wolkenstein P, Martin L. Late diagnosis of neurofibromatosis type 1 in an 81-year-old patient. Clin Exp Dermatol. 2015;40(2):225-6. DOI: 10.1111/ced.12403.
Ponti G, Losi L, Martorana D, Priola M, Boni E, Pollio A, et al. Clinico-pathological and biomolecular findings in Italian patients with multiple cutaneous neurofibromas. Hered Cancer Clin Pract. 2011;9:6. DOI: 10.1186/1897-4287-9-6.
Bongiorno MR, Cefalù AB, Aricò M, Averna M. Clinical, pathologic, and genetic features of massive soft tissue neurofibromas in a Sicilian patient. Dermatol Ther. 2008;21 Suppl 3:S21-5. DOI: 10.1111/j.1529-8019.2008.00237.x.
Mautner VF, Kluwe L, Friedrich RE, Roehl AC, Bammert S, Högel J, et al. Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions. J Med Genet. 2010 47(9):623-30. DOI: 10.1136/jmg.2009.075937.
Gabriele AL, Ruggieri M, Patitucci A, Magariello A, Conforti FL, Mazzei R, et al. A novel NF1 gene mutation in an Italian family with neurofibromatosis type 1. Childs Nerv Syst. 2011; 27(4):635-8. DOI: 10.1007/s00381-010-1282-z.
Kluwe L, Friedrich RE, Korf B, Fahsold R, Mautner VF. NF1 mutations in neurofibromatosis 1 patients with plexiform neurofibromas. Hum Mutat. 2002;19(3):309.
Pasmant E, Sabbagh A, Masliah-Planchon J, Ortonne N, Laurendeau I, Melin L. Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1. J Natl Cancer Inst. 2011;103(22):1713-22. DOI: 10.1093/jnci/djr416.
Mußotter T, Kluwe L, Högel J, Nguyen R, Cooper DN, Mautner VF, et al. Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions. BMC Med Genet. 2012;13:98. DOI: 10.1186/1471-2350-13-98.
Kluwe L, Nguyen R, Vogt J, Bengesser K, Mussotter T, Friedrich RE, et al. Internal tumor burden in neurofibromatosis Type I patients with large NF1 deletions. Genes Chromosomes Cancer. 2012;51(5):447-51. DOI: 10.1002/gcc.21931.
Upadhyaya M, Spurlock G, Kluwe L, Chuzhanova N, Bennett E, Thomas N, et al. The spectrum of somatic and germline NF1 mutations in NF1 patients with spinal neurofibromas. Neurogenetics. 2009;10(3):251-63. DOI: 10.1007/s10048-009-0178-0.
Nicita F, Torrente I, Spalice A, Bottillo I, Papetti L, Pinna V, et al. Spinal neurofibromatosis in a family with classical neurofibromatosis type 1 and a novel NF1 gene mutation. J Clin Neurosci. 2014;21(2):328-30. DOI: 10.1016/j.jocn.2013.01.026.
Wimmer K, Mühlbauer M, Eckart M, Callens T, Rehder H,Birkner T, et al. A patient severely affected by spinal neurofibromas carries a recurrent splice site mutation in the NF1 gene. Eur J Hum Genet. 2002;10(5):334-8.
Campen CJ, Gutmann DH. Optic pathway gliomas in neuro fibromatosis type 1. J Child Neurol. 2018;33(1):73-81. DOI: 10.1177/0883073817739509.
Sharif S, Upadhyaya M, Ferner R, Majounie E, Shenton A, Baser M, et al. A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations. J Med Genet. 2011;48(4):256-60. DOI: 10.1136/jmg.2010.081760.
Bolcekova A, Nemethova M, Zatkova A, Hlinkova K, Pozgayova S, Hlavata A, et al. Clustering of mutations in the 5’ tertile of the NF1 gene in Slovakia patients with optic pathway glioma. Neoplasma. 2013;60(6):655-65 DOI: 10.4149/neo_2013_084.
Castle B, Baser ME, Huson SM, Cooper DN, Upadhyaya M. Evaluation of genotype-phenotype correlations in neurofibromatosis type 1. J Med Genet. 2003; 40(10): e109.
Kehrer-Sawatzki H, Schmid E, Fünsterer C, Kluwe L, Mautner VF. Absence of cutaneous neurofibromas in an NF1 patient with an atypical deletion partially overlapping the common 1.4 Mb microdeleted region. Am J Med Genet A. 2008;146A(6):691-9. DOI: 10.1002/ajmg.a.32045.
Mensink KA, Ketterling RP, Flynn HC, Knudson RA, Lindor NM, Heese BA, Spinner RJ, Babovic-Vuksanovic D. Connective tissue dysplasia in five new patients with NF1 microdeletions: further expansion of phenotype and review of the literature. J Med Genet. 2006; 43(2): e8.
Laurito S, Di Pierri J, Roqué M. Neurofibromatosis tipo I: Mutación de splicing detectada por MLPA y secuenciación en la Argentina. Medicina (B. Aires) 2015; 75(2): 91-4.
Su SY, Zhou X, Pang XM, Chen CY, Li SH, Liu JL. NF1 frameshift mutation (c.6520_6523delGAGA) association with nervous system tumors and bone abnormalities in a Chinese patient with neurofibromatosis type 1. Genet Mol Res. 2016;15(2). DOI: 10.4238/gmr.15027572.
Kehrer-Sawatzki H, Kluwe L, Fünsterer C, Mautner VF. Extensively high load of internal tumors determined by whole body MRI scanning in a patient with neurofibromatosis type 1 and a non-LCR-mediated 2-Mb deletion in 17q11.2. Hum Genet. 2005;116(6):466-75.
Alkindy A, Chuzhanova N, Kini U, Cooper DN, Upadhyaya M. Genotype-phenotype associations in neurofibromatosis type 1 (NF1): an increased risk of tumor complications in patients with NF1 splice-site mutations? Hum Genomics. 2012;6:12. DOI: 10.1186/1479-7364-6-12.
Tong HX, Li M, Zhang Y, Zhu J, Lu WQ. A novel NF1 mutation in a Chinese patient with giant café-au-lait macule in neurofibromatosis type 1 associated with a malignant peripheral nerve sheath tumor and bone abnormality. Genet Mol Res. 2012;11(3):2972-8.
Campos B, Balmaña J, Gardenyes J, Valenzuela I, Abad O, Fàbregas P, Volpini V, Díez O. Germline mutations in NF1 and BRCA1 in a family with neurofibromatosis type 1 and earlyonset breast cancer. Breast Cancer Res Treat. 2013;139(2):597-602. DOI: 10.1007/s10549-013-2538-6.
Barquero LA, Sefcik AM, Cutting LE, Rimrodt SL. Teaching reading to children with neurofibromatosis type 1: a clinical trial with random assignment to different approaches. Dev Med Child Neurol. 2015 57(12):1150-8. DOI: 10.1111/dmcn.12769.
Diggs-Andrews KA, Gutmann DH. Modeling cognitive dysfunction in neurofibromatosis-1. Trends Neurosci. 2013 36(4):237-47. DOI: 10.1016/j.tins.2012.12.002.
Violante IR, Ribeiro MJ, Edden RA, Guimarães P, Bernardino I, Rebola J, et al. GABA deficit in the visual cortex of patients with Neurofibromatosis type 1: genotype-phenotype correlations and functional impact. Brain. 2013; 136(Pt 3):918-25. DOI: 10.1093/brain/aws368.
Cai SP, Fan N, Chen J, Xia ZL, Wang Y, Zhou XM, et al. A novel NF1 frame-shift mutation (c.702_703delGT) in a Chinese family with neurofibromatosis type 1. Genet Mol Res 2014; 24;13(3):5395-404. DOI: 10.4238/2014.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.